反応式
[C:1]([O:5][C:6]([N:8]1[CH2:11][CH:10]([N:12]2[CH2:17][CH2:16][NH:15][C:14](=[O:18])[CH2:13]2)[CH2:9]1)=[O:7])([CH3:4])([CH3:3])[CH3:2].Br[C:20]1[N:25]=[CH:24][CH:23]=[CH:22][N:21]=1.N1C2C(=CC=C3C=2N=CC=C3)C=CC=1.[O-]P([O-])([O-])=O.[K+].[K+].[K+]>C1(C)C=CC=CC=1.C(Cl)Cl.[Cu]I>[C:1]([O:5][C:6]([N:8]1[CH2:11][CH:10]([N:12]2[CH2:17][CH2:16][N:15]([C:20]3[N:25]=[CH:24][CH:23]=[CH:22][N:21]=3)[C:14](=[O:18])[CH2:13]2)[CH2:9]1)=[O:7])([CH3:4])([CH3:2])[CH3:3]参加物
8
反応物 4
生成物 1
試薬・触媒・溶媒 3
反応条件
- 温度
- 110 °C
実験手順
A mixture of intermediate 4b (52 mg, 0.204 mmol), 2-bromopyrimidine 1i (65 mg, 0.41 mmol), CuI (8 mg, 0.04 mmol), 1,10-phenanthroline (18 mg, 0.10 mmol), and K3PO4 (95 mg, 0.45 mmol) in toluene (1 mL) was heated at 110° C. under N2 for 9 h. The reaction mixture was diluted with CH2Cl2 and filtered. The solution was concentrated and purification by column chromatography (silica gel, 3% MeOH/CH2Cl2) gave intermediate 3c as light yellow solid (25 mg).
後処理
- filtrationfiltered
- concentrationThe solution was concentrated
- custompurification by column chromatography (silica gel, 3% MeOH/CH2Cl2)
出典と根拠
- ORDレコード
- ord-68440521ea3d43a188786ef8be7d78a5
- 出典データセット
- uspto-grants-2014_01
- 特許番号
- US08637498B2
関連ノート
読み込み中…